NCT05699070

Drug-drug Interactions Between DWC202211 and DWC202212 in Healthy Subjects

An Open-label Phase 1 Study to Evaluate Pharmacokinetic/Pharmacodynamic Drug-drug Interactions and Safety/Tolerability of DWC202211 and DWC202212 Compared to Coadministration in Healthy

• Status: Unknown
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 24 (estimated)
• Sponsor: Daewoong Pharmaceutical Co. LTD. · Industry
• Sex: All
• Age: 19 Years – 50 Years
• Healthy volunteers: Accepted

Summary

An open-label phase 1 study to evaluate pharmacokinetic/pharmacodynamic drug-drug interactions and safety/tolerability of DWC202211 and DWC202212 compared to coadministration in healthy

Conditions

• Drug-drug Interaction

Interventions

Type	Name	Description
DRUG	DWC202211 100mg	DWC202211 for 5 days Aspirin 100mg
DRUG	DWC202212 5mg	DWC202212 for 3 days Rabeprazole 5mg
DRUG	DWC202211 100mg + DWC202212 5mg	DWC202211 + DWC202212 for 5 days Aspirin 100mg, Rabeprazole 5mg

Timeline

• Start date: 2023-02-15
• Primary completion: 2023-04-24
• Completion: 2023-06-01
• First posted: 2023-01-26
• Last updated: 2023-04-04

Locations

1 site across 1 country: South Korea